CJC-1295 + Ipamorelin and Tirzepatide Together: What Is Known
CJC-1295 + Ipamorelin and Tirzepatide taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 1 result, 2 Oct 2026).
Side by side
Showing 11 of 13 fields where the two differ. PCAC vote, Jul 2026, Evidence strength are the same or both unknown.
| Field | CJC-1295 + Ipamorelin | Tirzepatide |
|---|---|---|
| Class | GHRH + GHRP blend | GLP-1 / GIP dual agonist |
| Also called | CJC/Ipa | tirz, tirze, Mounjaro, Zepbound |
| Category | Growth hormone | GLP-1 & metabolic |
| FDA status | Not FDA approved · research blend | FDA approved (Mounjaro, Zepbound) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)Both components are named in S2.2.4 (CJC-1295 as a GHRH analogue, ipamorelin as a secretagogue), so the blend is prohibited at all times. | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | Ipamorelin: 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658 | approximately 5 dayssubcutaneous · FDA label (Mounjaro) |
| Evidence strength | Human RCT evidence, 4 of 4Ipamorelin: International journal of colorectal disease 2014, PMID 25331030 | Human RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163 |
| Human studies we summarised | 6 human (3 randomized or controlled) of 19 summarised, across ingredients | 24 human (22 randomized or controlled) of 30 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 10 mg | 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg |
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026; 31 Mar 2026) |
What the blend's components have shown
Once-daily CJC-1295 maintained normal body composition and growth in GHRH-knockout mice.[16]
In rats, intranasal ipamorelin had an estimated bioavailability of about 20%.[17]
Tirzepatide in sleep apnea
In the SURMOUNT-OSA trial, apnea-hypopnea index fell by 25.3 events per hour with tirzepatide against 5.3 with placebo.[18]
Zepbound's label says it delays gastric emptying and reports rare cases of pulmonary aspiration in patients on GLP-1 receptor agonists undergoing procedures that need general anesthesia or deep sedation.[19]
Label warning on the tirzepatide side
Tirzepatide's boxed warning concerns rat thyroid C-cell tumours with an undetermined human relevance.[19]
Which CJC-1295 do the human data cover?
A recent review of GH-axis peptides separates CJC-1295 with DAC from CJC-1295 without DAC.[20]
One paper describes CJC-1295 as an analog that binds permanently to albumin after injection, with a half-life of 8 d, so the human data it reports are for that albumin-binding form.[21]
Together
The search for the blend with tirzepatide returned 1 PubMed record, and it is not classed as a study of both.
Calculated from pubmed query (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab]); search date 2026-10-02; records returned 1; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key cjc-1295-ipamorelin__tirzepatide); no arithmetic applied.
CJC-1295 has no product listed in Drugs@FDA.[14]
Common questions
Can you take CJC-1295/ipamorelin with tirzepatide?
Nothing in the cited records tests the combination. Zepbound's label says tirzepatide delays gastric emptying.[19]
CJC-1295 ipamorelin vs tirzepatide: what is the difference?
Tirzepatide has a randomised sleep-apnea trial with a measured endpoint, the apnea-hypopnea index. The blend has no trial of its own.[18]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 5Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
- 6Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
- 7Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
- 8Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
- 9These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 10Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
- 11Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
- 12Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
- 13PubMed search: (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 15Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
- 16Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
- 17Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.Xenobiotica; the fate of foreign compounds in biological systems · 1998PMID 9879640Accessed 2 Oct 2026
- 18Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.The New England journal of medicine · 2024PMID 38912654Accessed 2 Oct 2026
- 19ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 20The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
- 21Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
Found an error? Report a correction.